Literature DB >> 9013365

Pharmacokinetics of prednisolone during administration of sirolimus in patients with renal transplants.

W J Jusko1, G M Ferron, S M Mis, B D Kahan, J J Zimmerman.   

Abstract

The pharmacokinetic interaction of multiple oral doses of sirolimus (rapamycin) and prednisone were evaluated in 40 stable patients with renal transplants receiving concomitant multiple doses of cyclosporine. Nine sirolimus dosage levels from 1 mg/m2/day to 13 mg/m2/day were studied and compared with placebo. Plasma concentrations of prednisone, prednisolone, and cortisol were measured by high-performance liquid chromatography and analyzed by noncompartmental methods. Mean pharmacokinetic values of prednisolone found before sirolimus administration were as follows: peak plasma concentration (Cmax) was 187 ng/mL; time to peak plasma concentration (tmax) was 2.03 hours; rate of reaching peak plasma concentration (Cmax divided by the area under the concentration-time curve [AUC]) was 0.149 hour-1; terminal half-life (t1/2) was 3.60 hours; AUC was 1206 ng.hour/mL; and apparent clearance (Cl/F) was 0.094 L/hour/kg. During the 2 weeks of concomitant administration, prednisolone elimination decreased in relation to sirolimus dosages. These changes were modest, with mean increases of 18% in Cmax and 27% in t1/2 and mean decreases of 27% in Cl/F for the groups receiving 6 mg/m2/day to 13 mg/m2/day. Most patients initially had plasma cortisol concentrations indicative of adrenal suppression. With sirolimus treatment, the Cmax of cortisol did not decrease further, but the AUC (8:00 AM-8:00 PM) values were significantly lower, independent of sirolimus exposure. The AUC for cyclosporine did not correlate with sirolimus and prednisolone exposure. A 2-week course of sirolimus showed a slight pharmacokinetic interaction between sirolimus and prednisolone/prednisone/cortisol in stable patients with renal transplants.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9013365     DOI: 10.1002/j.1552-4604.1996.tb04162.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  16 in total

1.  Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in rabbits.

Authors:  G M Ferron; W J Jusko
Journal:  Pharm Res       Date:  1998-12       Impact factor: 4.200

2.  Pharmacokinetics of total and unbound prednisone and prednisolone in stable kidney transplant recipients with diabetes mellitus.

Authors:  Ileana A Ionita; Ken Ogasawara; Reginald Y Gohh; Fatemeh Akhlaghi
Journal:  Ther Drug Monit       Date:  2014-08       Impact factor: 3.681

Review 3.  Immunosuppressive therapy for paediatric transplant patients: pharmacokinetic considerations.

Authors:  María del Mar Fernández De Gatta; Dolores Santos-Buelga; Alfonso Domínguez-Gil; María José García
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

4.  Gender-related assessment of cyclosporine/prednisolone/sirolimus interactions in three human lymphocyte proliferation assays.

Authors:  G M Ferron; N A Pyszczynski; W J Jusko
Journal:  Transplantation       Date:  1998-05-15       Impact factor: 4.939

5.  Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in adrenalectomized rats.

Authors:  G M Ferron; N A Pyszczynski; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1999-02

Review 6.  Clinical pharmacokinetics of sirolimus.

Authors:  K Mahalati; B D Kahan
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

7.  Suppressed calcineurin-dependent gene expression identifies lung allograft recipients at increased risk of infection.

Authors:  John R Greenland; Tiffany Chong; Angelia S Wang; Emily Martinez; Pavan Shrestha; Jasleen Kukreja; Steven R Hays; Jeffrey A Golden; Jonathan P Singer; Qizhi Tang
Journal:  Am J Transplant       Date:  2018-05-22       Impact factor: 8.086

Review 8.  Clinical pharmacokinetics and pharmacodynamics of prednisolone and prednisone in solid organ transplantation.

Authors:  Troels K Bergmann; Katherine A Barraclough; Katie J Lee; Christine E Staatz
Journal:  Clin Pharmacokinet       Date:  2012-11       Impact factor: 6.447

Review 9.  Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.

Authors:  David Czock; Frieder Keller; Franz Maximilian Rasche; Ulla Häussler
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

10.  Sirolimus steady-state trough concentrations are not affected by bolus methylprednisolone therapy in renal allograft recipients.

Authors:  L Bäckman; H Kreis; J M Morales; H Wilczek; R Taylor; J T Burke
Journal:  Br J Clin Pharmacol       Date:  2002-07       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.